Quality of Life in a Randomized, Double-Blind, Placebo-Controlled Study of Oxybutynin Chloride Topical Gel Treatment of Patients With Overactive Bladder

Hypothesis/aims of study Oxybutynin chloride topical gel (OTG) is a 10% by weight ethanolic gel formulation that is applied to the skin once daily [1,2]. The efficacy of OTG in improving urinary symptoms associated with overactive bladder (OAB) was demonstrated in a 12-week, multicenter, randomized, double-blind, placebo-controlled phase 3 study [3]. OTG significantly reduced the number of incontinence episodes per day, decreased urinary frequency, and increased voided volumes versus placebo [3]. The effects of OTG on healthrelated quality of life (HRQoL), a planned secondary end point in the study, were evaluated in order to measure patients’ perceptions of improvement in their OAB symptoms.